Corpus overview


Overview

MeSH Disease

Human Phenotype

There are no HP terms in the subcorpus


Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 2 records in total 2
    records per page




    A Strategy to Treat COVID-19 Disease MESHD with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Non-clinical Pharmacokinetic Study

    Authors: Tien-Tzu Tai; Tzung-Ju Wu; Huey-Dong Wu; Yi-Chen Tsai; Hui-Ting Wang; An-Min Wang; Sheue-Fang Shih; Yee-Chun Chen

    doi:10.1101/2020.07.09.196618 Date: 2020-07-10 Source: bioRxiv

    Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) is a newly identified pathogen causing coronavirus disease MESHD 2019 (COVID-19) pandemic. Hydroxychloroquine (HCQ), an antimalarial and anti-inflammatory drug, has been shown to inhibit SARS-CoV-2 infection MESHD in vitro and tested in clinical studies. However, lung concentration (6.7 {micro}g/mL) to predict the in vivo antiviral efficacy might not be achievable with the currently proposed oral dosing regimen. Further, a high cumulative doses of HCQ may raise concerns of systemic toxicity MESHD, including cardiotoxicity MESHD. Here, we described a non-clinical study to investigate the pharmacokinetics of a novel formulation of liposomal HCQ administrated by intratracheal (IT) instillation in Sprague-Dawley (SD) rats which achieved 129.4 {micro}g/g (Cmax) in the lung. Compared to unformulated HCQ administered intravenous (IV), liposomal HCQ with normalized dose showed higher ([~]30-fold) lung exposure, longer ([~]2.5-fold) half-life in lung, but lower blood SERO exposure with [~]20% of Cmax and 74% of AUC and lower heart exposure with 24% of Cmax and 58% of AUC. In conclusion, the pharmacokinetics results in an animal model demonstrate the proof of concept that inhalable liposomal HCQ may provide clinical benefit and serve as a potential treatment for COVID-19.

    Cardiovascular Vulnerability to COVID-19 in Cancer MESHD Survivors

    Authors: Beshay Zordoky

    id:10.20944/preprints202004.0128.v1 Date: 2020-04-08 Source: Preprints.org

    Coronavirus disease MESHD 2019 (COVID-19) has been declared a global pandemic by the World Health Organization on March 11, 2020. COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 MESHD (SARS-Cov-2). Although primarily a respiratory disease MESHD, cardiovascular complications MESHD of COVID-19 have been increasingly recognized. In addition, higher fatality has been reported in COVID-19 patients with underlying cardiovascular diseases MESHD. Cancer MESHD survivors have a considerably increased risk for premature cardiovascular diseases MESHD, mainly due to cardiotoxic cancer MESHD treatments. Therefore, it is foreseeable that cancer MESHD survivors will be more vulnerable to cardiovascular complications MESHD caused by COVID-19. In this review, three scenarios for increased cardiovascular complications of COVID-19 in cancer MESHD patients are proposed. In the first scenario, cardiotoxic cancer MESHD treatment and COVID-19 synergize to exacerbate direct myocardial damage MESHD. In the second scenario, cardiotoxic cancer MESHD treatment leads to a reduced cardiac reserve in cancer MESHD survivors, making them more vulnerable to COVID-19 in a “two-hit” model. The third scenario suggests that several shared risk factors may aggravate cardiovascular complications MESHD caused by both cancer MESHD treatment and COVID-19. Taken together, cancer MESHD survivors may be more vulnerable to cardiovascular complications MESHD when challenged by the COVID-19, and special cardiovascular care should be given to these patients.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.